The year is drawing to a close, and I have not been forced to release a statement that I am leaving The Rheumatologist “to spend more time with my family.” Once again, improbably, I have made it to the finish line. Given that, now seems to be a good time to reflect, and to give…
Three full-time, ACR advocacy staffers are now working in Washington, D.C., to provide a daily presence for national rheumatology lobbying efforts.
I had the opportunity to attend the Rheumatology Research Workshop in Washington, D.C., in June 2019. Held annually, this two-day meeting is run by the ACR Early Career Investigators (ECI) Subcommittee and is geared toward trainees at all levels (fellows, residents and medical students) and junior faculty with an interest in a rheumatology research career….
ATLANTA—Dry eyes and mouth are common symptoms in the general population. When patients report these symptoms to their primary care provider and other consultants, it may prompt a referral to a rheumatologist to rule out Sjögren’s syndrome. However, as discussed in the 2019 ACR/ARP Annual Meeting session, Sjögren’s Syndrome: Beyond the Dryness, evaluation of this…
Karen Onel, MD, new chair of ACR’s Committee on Ethics & Conflict of Interest, brings a longstanding interest in issues related to ethics and consent.
Contributions from ACR/ARP members and volunteer leaders raised more than $36,000 in November to support rheumatology advocacy efforts.
WASHINGTON (Reuters)—U.S. President Donald Trump said on Friday, Nov. 22, he will soon release a plan to let Florida and other states import prescription medicines to combat high drug prices. He blasted the Democrat-led U.S. House of Representatives for not going far enough in a drug-pricing bill. “We will soon be putting more options on…
Sindhu Johnson, MD, PhD, FRCPC, has co-chaired the classification and response criteria subcommittee and brings extensive experience in classification and guideline development to her new role.
The ACR’s delegation to the AMA HOD meeting in November successfully advanced resolutions to advocate for pharmacy benefit manager transparency and expanded patient protections from step therapy protocols.
ATLANTA—In the late 1990s, at the Annual Meeting, a colleague asked Marian Hannan, DSc, MSc, who is now professor of medicine at Harvard Medical School, if she wanted to go to a tourist attraction and talk about professional pursuits during a break at the conference. The colleague ranked higher than she did, and she didn’t…